Fidelity Investments
ACTU

Fidelity Investments’s Actuate Therapeutics ACTU Stock Holding History

Fidelity Investments’s Portfolio ACTU Stock Details ACTU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.03K Sell
3,287
-5,658
-63% -$13.1K ﹤0.01% 5011
2026
Q1 		$24.5K Buy
8,945
+8,665
+3,095% +$35.9K ﹤0.01% 4436
2025
Q4 		$1.71K Sell
280
-293
-51% -$2.01K ﹤0.01% 5034
2025
Q3 		$3.83K Buy
573
+262
+84% +$1.9K ﹤0.01% 4838
2025
Q2 		$1.9K Buy
+311
New +$2.72K ﹤0.01% 4866

Other funds holding ACTU

BCM
BIOS Capital Management Fort Worth, Texas $41.7M AUM 34.92% 1-Year Est. Return
VC
Voss Capital Houston, Texas $2.15B AUM 33.46% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
TCBWMS
Texas Capital Bank Wealth Management Services Dallas, Texas $1.87B AUM 24.49% 1-Year Est. Return
PVM
Palogic Value Management Dallas, Texas $304M AUM 15.15% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ADEF
ABS Direct Equity Fund Stamford, Connecticut $159M AUM 34.17% 1-Year Est. Return

Fidelity Investments's ACTU Position: Q2 2026 in Review

Fidelity Investments reduced its Actuate Therapeutics (ACTU) stake by 63% in Q2 2026, selling an estimated $13.1K and leaving 3,287 shares worth $5.03K. The position accounts for ﹤0.01% of the portfolio, ranked #5011.

Fidelity Investments first reported a position in ACTU in Q2 2025 and has held it in 5 quarters since. The position peaked at $24.5K in Q1 2026. 64 funds tracked by Wall St. Rank hold ACTU as of Q2 2026.

  • Fidelity Investments held 3,287 shares of Actuate Therapeutics worth $5.03K as of Q2 2026.
  • Fidelity Investments sold 5,658 Actuate Therapeutics shares in Q2 2026, an estimated $13.1K.
  • Actuate Therapeutics made up ﹤0.01% of Fidelity Investments's portfolio in Q2 2026, its #5011 holding.
  • Fidelity Investments first reported a position in Actuate Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • Fidelity Investments's Actuate Therapeutics position peaked at $24.5K in Q1 2026.
  • 64 funds tracked by Wall St. Rank held Actuate Therapeutics as of Q2 2026.

Based on Fidelity Investments's 13F filing for Q2 2026, filed 13 Aug 2026.